Bridgeway Capital Management, LLC Spero Therapeutics, Inc. Transaction History

Bridgeway Capital Management, LLC

$3.75 Billion
Q1 2025

A detailed history of Bridgeway Capital Management, LLC transactions in Spero Therapeutics, Inc. stock. As of the latest transaction made, Bridgeway Capital Management, LLC holds 154,800 shares of SPRO stock, worth $105,264. This represents 0.0% of its overall portfolio holdings.

Number of Shares

154,800

Previous 184,800 16.23%

Holding current value

$105,264

Previous $192,000 42.19%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$0.72 - $1.1 $21,600 - $33,000	-30,000 Reduced 16.23%	154,800 $111,000
Q1 2024 May 15, 2024	BUY	$1.35 - $1.79 $67,500 - $89,500	50,000 Added 37.09%	184,800 $317,000
Q3 2023 Nov 14, 2023	BUY	$1.2 - $1.63 $30,000 - $40,750	25,000 Added 22.77%	134,800 $163,000
Q1 2023 May 15, 2023	BUY	$1.35 - $2.0 $148,230 - $219,600	109,800 New	109,800 $159,000
Q2 2020 Aug 14, 2020	SELL	$7.27 - $14.18 $503,847 - $982,744	-69,305 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$5.27 - $10.41 $6,713 - $13,262	-1,274 Reduced 1.81%	69,305 $560,000
Q4 2019 Feb 14, 2020	BUY	$9.46 - $12.16 $151,360 - $194,560	16,000 Added 29.32%	70,579 $679,000
Q1 2019 May 15, 2019	BUY	$6.26 - $13.31 $162,760 - $346,060	26,000 Added 90.98%	54,579 $699,000
Q4 2018 Feb 14, 2019	SELL	$5.69 - $11.28 $284,500 - $564,000	-50,000 Reduced 63.63%	28,579 $176,000
Q3 2018 Nov 13, 2018	BUY	$9.69 - $17.79 $231,387 - $424,807	23,879 Added 43.65%	78,579 $826,000
Q1 2018 May 15, 2018	BUY	$9.96 - $14.61 $544,812 - $799,167	54,700 New	54,700 $779,000

Others Institutions Holding SPRO

# of Institutions

Shares Held

18.4M

Call Options Held

9.3K

Put Options Held

100

View Full List

About Spero Therapeutics, Inc.

Ticker SPRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,067,500
Market Cap $23.8M
Description
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to ...

More about SPRO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bridgeway Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Bridgeway Capital Management, LLC with notifications on news.

Account

Bridgeway Capital Management, LLC Spero Therapeutics, Inc. Transaction History